| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | 3 | +$24.0K | Bought Aug 20, 26 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Aug 20, 26 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Sep 10, 26 (21d) | |
| Mar 3, 26 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Apr 7, 26 (35d) | |
| May 6, 25 | Gilbert Cisneros CA31 | Self | Buy | $1,001 - $15,000 | Jun 6, 25 (31d) |
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Privitera SalvatoreChief Technology Officer | Sale at price 60.00 per share. | 4.5K | $271.14K |
| Sep 10, 2026 | Groves Regina EDirector | Sale at price 54.22 per share. | 5.3K | $288.07K |
| Sep 7, 2026 | Privitera SalvatoreChief Technology Officer | Sale at price 55.00 per share. | 3.7K | $201.13K |
| Sep 1, 2026 | Privitera SalvatoreChief Technology Officer | Sale at price 52.50 per share. | 7.8K | $407.56K |
| Aug 23, 2026 | Dahlquist Karl SOfficer | Sale at price 48.89 per share. | 9.4K | $458.10K |
| Aug 4, 2026 | Prange Karen N.Director | Sale at price 38.80 per share. | 3.6K | $138.28K |
| Aug 4, 2026 | Yuen Maggie S.Director | Sale at price 38.42 per share. | 3.5K | $134.47K |
| Jul 29, 2026 | Carrel Michael HChief Executive Officer | Stock Gift at price 0.00 per share. | 4.7K | — |
| Jul 28, 2026 | Noznesky Justin JOfficer | Sale at price 38.80 per share. | 6.2K | $239.86K |
| Jul 27, 2026 | Doraiswamy VinayakOfficer | Sale at price 38.88 per share. | 6K | $233.28K |
| Jul 27, 2026 | Wehrwein Sven ADirector | Sale at price 37.84 per share. | 25K | $946.00K |
| Jul 27, 2026 | Wehrwein Sven ADirector | Conversion of Exercise of derivative security at price 19.95 per share. | 25K | $498.75K |
| Jun 29, 2026 | Seith Douglas JChief Operating Officer | Stock Award(Grant) at price 23.78 per share. | 527 | $12.53K |
| Jun 29, 2026 | Doraiswamy VinayakOfficer | Stock Award(Grant) at price 23.78 per share. | 636 | $15.12K |
| Jun 29, 2026 | Dahlquist Karl SOfficer | Stock Award(Grant) at price 23.78 per share. | 636 | $15.12K |
| Jun 29, 2026 | Carrel Michael HChief Executive Officer | Stock Award(Grant) at price 23.78 per share. | 636 | $15.12K |
| Jun 29, 2026 | Privitera SalvatoreChief Technology Officer | Stock Award(Grant) at price 23.78 per share. | 636 | $15.12K |
| May 19, 2026 | Prange Karen N.Director | Sale at price 28.65 per share. | 3K | $85.95K |
| May 17, 2026 | Prange Karen N.Director | Stock Award(Grant) at price 0.00 per share. | 6.1K | — |
| May 17, 2026 | White Robert SDirector | Stock Award(Grant) at price 0.00 per share. | 6.1K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.6 | -15.4 | -8.7 | -1.5 | -1.6 | 1.1 | 35.0 | 28.0 | 16.2 | 1.9 | +44.8% | ||
| 2025 | 30.5 | -2.8 | -16.7 | -7.3 | 15.6 | -5.2 | 7.1 | 5.4 | -4.7 | -2.0 | 4.5 | 9.5 | +29.5% |
| 2024 | -4.6 | 2.7 | -13.0 | -20.7 | -6.6 | 1.0 | -5.3 | 21.5 | 7.0 | 18.3 | 9.0 | -15.5 | −14.4% |
| 2023 | -2.5 | -11.0 | 7.7 | 6.1 | 2.2 | 9.8 | 12.1 | -18.4 | -3.0 | -20.9 | 2.4 | 0.6 | −19.6% |
| 2022 | -5.6 | 5.8 | -5.4 | -20.9 | -21.8 | 0.6 | 20.9 | -7.7 | -14.3 | 7.7 | 8.2 | -2.6 | −36.2% |
| 2021 | 4.6 | 12.1 | 0.4 | 17.6 | -3.0 | 6.2 | 6.5 | -12.8 | -5.5 | 7.9 | -15.5 | 9.7 | +24.9% |
| 2020 | 19.7 | -1.2 | -12.6 | 28.4 | 10.9 | -6.0 | -9.2 | 9.6 | -10.8 | -13.4 | 25.8 | 28.0 | +71.2% |
| 2019 | 1.1 | 3.2 | -16.1 | 12.1 | -2.4 | 1.8 | 7.5 | -14.6 | -8.9 | 6.6 | 11.9 | 9.3 | +6.2% |
| 2018 | -10.6 | 8.3 | 16.1 | 8.3 | 6.7 | 14.1 | 5.9 | 20.6 | 1.4 | -9.2 | 5.3 | -8.6 | +67.8% |
| 2017 | -16.9 | 12.2 | 4.9 | 7.0 | 1.9 | 16.1 | -0.1 | -7.4 | -0.3 | -4.2 | -13.7 | -1.4 | −6.8% |
| 2016 | -22.1 | -5.2 | 1.6 | -5.5 | -8.9 | -2.5 | 7.5 | 1.3 | 2.8 | 15.3 | -1.4 | 8.8 | −12.8% |
| 2015 | -0.6 | -10.9 | 15.9 | 7.4 | 4.2 | 7.4 | 12.8 | -12.0 | -10.4 | -15.5 | 16.0 | 4.5 | +12.4% |
| 2014 | 9.7 | 1.4 | -9.5 | -18.1 | 7.3 | 11.3 | -10.4 | -5.8 | -5.2 | 18.5 | 7.4 | 6.6 | +6.9% |
| 2013 | 16.8 | 10.2 | -10.8 | 5.3 | 8.5 | 5.0 | 1.7 | -9.0 | 24.9 | 26.1 | 13.1 | 19.3 | +170.7% |
| 2012 | 3.8 | -11.5 | -2.5 | -17.6 | 9.6 | 6.9 | -12.9 | -16.6 | 6.6 | -13.7 | 5.1 | 2.2 | −37.8% |
| 2011 | 7.1 | -8.7 | 13.3 | 18.9 | 5.1 | -9.3 | -5.7 | -15.7 | -5.1 | 14.6 | -9.1 | 9.5 | +8.1% |
| 2010 | -4.3 | -12.8 | 16.9 | -5.4 | -8.4 | 30.4 | -4.7 | 22.4 | 1.4 | 0.5 | 13.5 | 14.4 | +70.0% |
| 2009 | -39.2 | -2.2 | -3.0 | -4.7 | 98.4 | 44.6 | -0.3 | 12.3 | 20.4 | -13.6 | 33.6 | 10.8 | +172.1% |
| 2008 | 6.3 | -14.6 | 7.1 | 4.9 | -26.6 | 10.1 | -10.6 | 6.2 | -3.3 | -35.2 | -61.5 | -10.1 | −83.1% |
| 2007 | 17.4 | -3.7 | 1.0 | 9.6 | -11.5 | -13.7 | 14.2 | 7.8 | 1.2 | 7.0 | 1.0 | 14.1 | +46.6% |
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Buy / hold / sell counts